Trial Profile
A Phase II, Randomised, Double-blind, Placebo-controlled Study of MT-3995 (Low Dose) in Subjects With Diabetic Nephropathy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Apararenone (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 15 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 13 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 04 Aug 2014 New trial record